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Abstract
The present study measured prolactin, cortisol, ACTH and growth hormone in healthy male volunteers
following an acute oral administration of quetiapine, an atypical antipsychotic with high aﬃnity for H1
and moderate aﬃnity for s, a1, 5-HT2, a2 and D2 receptors. Fifteen male volunteers entered this ran-
domizeddouble-blind, cross-over, placebo-controlled study. Blood sampleswere drawnevery 30 min from
09:00 hours to 13:00 hours. The ﬁrst samples were drawn immediately before the administration of 150 mg
quetiapine or placebo. Mean results for each hormone and ANOVA for repeated measures were per-
formed. The area under the curve (AUC) hormonal values were calculated and compared by paired t test.
The ANOVA showed an increase of prolactin after quetiapine administration from time 60 min up to the
end of the observation period. Cortisol decreased after quetiapine administration from time 150 min to
time 240 min. ACTH secretion showed no diﬀerence compared to placebo. There was a late increase in
growth hormone secretion, signiﬁcant in comparison with placebo only at time 210 min. The AUC values
were statistically diﬀerent for prolactin and cortisol compared to placebo. A single dose of quetiapine
(150 mg) increased prolactin secretion probably due to a transiently high D2 receptor occupancy at the
anterior pituitary. Cortisol secretion decreased as was expected from quetiapine’s pharmacodynamic
proﬁle. The lack of response of ACTH might be, at least in part, explained by the low hormonal assay
sensitivity. The late growth hormone increase might have been due to quetiapine’s antagonism of H1
receptors.
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Introduction
Studies of neuroendocrine eﬀects of antipsychotics
have been concentrated on prolactin (Prl), with the
other hormones playing a secondary role. This is
probably due to the role assigned to dopaminergic
pathways in the pathophysiological hypotheses of
psychosis (Meltzer and Deutsch, 1999). Those studies
have shown an increase in Prl secretion, secondary to
dopaminergic antagonism at the anterior pituitary and
have been conducted in patients and healthy volun-
teers (Garver, 2000). Hyperprolactinaemia is respon-
sible for many endocrine side-eﬀects of antipsychotics,
e.g. decreased libido, galactorrhoea.
In fact the increased Prl secretion seems the most
consistent biological marker of the eﬀects of anti-
psychotics in healthy volunteers among many neuro-
psychological, neurophysiological, neuroendocrine
tests and subjective eﬀects (de Visser et al., 2001).
Moreover, the doses of antipsychotics necessary to
induce Prl elevation were clearly related to their
aﬃnity for D2 receptors and the recommended initial
therapeutic dosage.
Diﬀerent neuroendocrine eﬀects would be expected
from atypical antipsychotics, since they diﬀer from
classic antipsychotics on pharmacodynamic proﬁles.
In fact, one of the proposed criteria to distinguish
typical from atypical antipsychotics is that the latter do
not induce sustained elevations in Prl secretion
(Markowitz et al., 1999). The simultaneous antagonism
of serotonergic and dopaminergic receptors (5-HT2/
D2), probably related to its antipsychotic activity, may
change the secretion of hormones like growth hor-
mone (GH) and cortisol (Cor) through serotonergic
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pathways. Serotonergic agonists may increase GH and
Cor blood levels, whereas antagonists may reduce
them, but data are still inconclusive (de Visser et al.,
2001).
Quetiapine is a dibenzothiazepine antipsychotic
with a tmax of 2 h and a half-life of approx. 7 h. It is an
antagonist with high aﬃnity for H1 histaminergic
receptors ; moderate aﬃnity for s (opiate), a1 and a2
adrenergic, 5-HT2 serotonergic and D2 dopaminergic
receptors ; low aﬃnity for 5-HT1A serotonergic and D1
dopaminergic receptors, and practically no aﬃnity for
benzodiazepinic binding sites or muscarinic receptors
(Caccia, 2000; Green, 1999).
Some studies have demonstrated that quetiapine
does not produce sustained elevations of Prl con-
centrations (Arvanitis et al., 1997 ; Kapur et al., 2000;
King et al., 1998; Small et al., 1997 ; Wetzel et al., 1995),
and some patients even showed a small decrease in Prl
levels (Arvanitis et al., 1997).
The low incidence of extrapyramidal side-eﬀects
and the lack of a sustained increase in Prl concen-
trations are explained by quetiapine’s low aﬃnity for
D2 receptors coupled with its high aﬃnity for H1 and
5-HT2 receptors. In fact, Kapur et al. (2000) investi-
gated the in-vivo eﬀects of quetiapine on D2 and 5-HT2
receptors using positron emission tomography, and
found a signiﬁcant occupation of D2 receptors
(58–64%, with [11C]raclopride), 2–3 hours after a single
dose of quetiapine followed by a signiﬁcant decrease
to very low levels (0–27%) 12 h later. Their study has
also shown that quetiapine does not produce sus-
tained Prl level elevation.
The aim of this study was to assess the hormonal
responses [Prl, Cor, adrenocorticotropic hormone
(ACTH) and GH] to an acute single dose of quetiapine
in healthy volunteers.
Method
Subjects
Fifteen healthy male volunteers, undergraduate
students, age ranging from 18 to 21 yr (mean 20 yr),
body mass index (BMI) (mean¡S.D.) 22.64¡2.86, were
included after signing an informed consent. The
Ethical Committee of the Federal University of Sa˜o
Paulo had approved the study. Their physical and
mental health was evaluated through a structured
interview (Structured Clinical Interview for DSM-IV
Axis I Disorders – Non-patient Version ; First et al., 1996),
physical examination, laboratory tests (haemogram,
Na+, K+, glucose, serum creatinine, uric acid, aspar-
tate aminotransferase, alanine aminotransferase and
bilirubin) and an electrocardiogram. Abnormal results,
history of psychiatric disorders and history of familiar
psychiatric disorders (ﬁrst-degree relatives) were ex-
clusion criteria. None of the volunteers was excluded
from the study.
Procedure
Quetiapine (150 mg) and placebo were administered
in a double-blind, randomized, cross-over design. The
dose of 150 mg was chosen because it is within the
clinically eﬀective dose range, although it is higher
than the initial dose. Fasting volunteers arrived at
07:30 hours the research centre and at 08:00 hours an
i.v. catheter was inserted into an antecubital vein and
kept open with heparinized saline (20 ml saline :0.5 ml
heparin, 25000 IU/5 ml). Then, they had a low-fat
breakfast (from 08:00 to 08:30 hours) and were admit-
ted in the study room, where they remained in bed
during the whole experiment. Blood samples were
drawn every 30 min from 09:00 to 13:00 hours. The
ﬁrst sample was drawn immediately before the in-
gestion of 150 mg quetiapine or placebo. One week
later, the procedure was repeated. Volunteers who
had taken quetiapine took placebo and vice versa.
The concentrations of Prl, Cor, ACTH and GH were
measured in each blood sample.
Hormonal assay
Blood samples for Prl, Cor and GH assays were col-
lected in tubes without additives ; serum was separ-
ated by centrifugation and stored at x20 xC. Samples
for the ACTH assays were drawn into refrigerated
tubes containing EDTA; serum was separated by
refrigerated centrifugation and stored atx20 xC.
Cor, GH and Prl levels were measured by an
immunoenzymometric assay (Tosoh AIA System
Analyses ; Tosoh Corporation, Tokyo, Japan). The
method sensitivities were 0.5 ng/ml for Prl, 0.1 ng/ml
for GH, and 0.2 mg/dl for Cor. The intra- and inter-
assay coeﬃcients of variation were 6.8% and 4.3% for
Prl, 5.4% and 2.7% for GH and 5.9% and 6.7% for
Cor respectively. ACTH levels were determined by a
chemiluminescent enzyme immunoassay (Immulite
System, DPC Diagnostic Products Corporation, Los
Angeles, CA, USA). The sensitivity of the method was
10.0 pg/ml with intra- and inter-assay coeﬃcients of
variation of 6.1% and 8.3% respectively.
Side-eﬀects
Side-eﬀects were evaluated with a modiﬁed Ugvalg
for Kliniske Undersgelser (UKU) side-eﬀect rating
scale (Lingjaerde et al., 1987), at 120 and 240 min after
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quetiapine or placebo administration. Among the four
groups of side-eﬀects assessed by the scale (psychic,
neurological, autonomic and other), only items related
to early side-eﬀects, e.g. somnolence/sedation, dysto-
nia, xerostomia and tachycardia, were evaluated.
Statistical analysis
Hormonal data were analysed with a two-way analy-
sis of variance (ANOVA) for repeated measures (time:
0, 30, 60, 90, 120, 150, 180, 210, and 240 min; treatment :
quetiapine, placebo) followed by Tukey’s test when
necessary. Greenhouse–Geisser and Huynh–Feldt
corrections were used for the error term in the
repeated-measures analysis.
Areas under the curve (AUCs), representing the Prl,
Cor, ACTH and GH total secretions, were calculated
with trapezoidal rule and compared using the
Student’s t test for paired samples.
In all tests, p<0.05 values were considered statisti-
cally signiﬁcant.
Results
Prl baseline concentrations (mean¡S.E.) were in the
normal range for both quetiapine (8.13¡0.90) and
placebo (8.02¡0.95). In the placebo group, Prl
serum concentration remained almost the same
throughout the experiment. Thirty minutes after the
administration of quetiapine, Prl concentration had
increased. After 90 min, it had tripled the basal level
(Figure 1).
Prl blood levels changed signiﬁcantly after quetia-
pine [treatment factor, F(1, 14)=40.90, p<0.001], Prl
levels changed signiﬁcantly along the experiment in
the quetiapine group [time factor, F(8, 112)=4.84,
p<0.001] and there were signiﬁcant diﬀerences in
the treatmentrtime interaction [interaction factor,
F(8, 112)=6.41, p<0.001]. Prl levels did not change
after placebo. After Greenhouse–Geisser and Huynh–
Feldt corrections, diﬀerences remained signiﬁcant.
Total Prl secretion during the experiment was sig-
niﬁcantly greater after the administration of quetia-
pine than after placebo. Indeed, the AUC for the Prl
group was signiﬁcantly greater than the one for
the placebo group [quetiapine (mean¡S.E.) : 65.24¡
20.91 ng/mlr240 min; placebo (mean¡S.E.) : 28.17¡
11.71 ng/mlr240 min; t=6.42, p<0.001].
There was a decrease in Cor concentrations follow-
ing both placebo and quetiapine during the 4 h of data
collection (Figure 2). From 150 min onwards, such
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Figure 1.Mean (¡S.E.) prolactin plasma levels (ng/ml) after the administration of 150 mg quetiapine (–&–) and placebo (- -$- -)
to healthy volunteers (n=15). Two-way ANOVA factors : treatment F(1, 14)=40.90, p<0.001 ; time F(8, 112)=4.84, p<0.001 ;
interaction F(8, 112)=6.41, p<0.001. Tukey’s tests : * p<0.05, compared to baseline ; # p<0.01, compared to placebo. Inset : mean
(¡S.E.) area under curve (AUC) for 150 mg quetiapine and placebo. Paired t test=6.42, # p<0.001.
Neuroendocrine eﬀects of quetiapine in healthy volunteers 51
 by guest on June 1, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
decrease was steeper in the quetiapine group than in
the placebo one [treatment factor, F(1, 14)=10.83,
p<0.01]. By the end of the experiment, Cor concen-
tration with quetiapine was less than half of that with
placebo. After quetiapine but not after placebo ad-
ministration, there was a signiﬁcant decrease in Cor
levels [time factor, F(8, 112)=26.82, p<0.001]. There
were signiﬁcant interactions between time and treat-
ment [interaction factor, F(8, 112)=11.2, p<0.001].
After Greenhouse–Geisser and Huynh–Feldt correc-
tions, diﬀerences remained signiﬁcant.
Total Cor secretion with quetiapine was lower
than with placebo [quetiapine (mean¡S.E.) : 28.75¡
9.37 mg/dlr240 min; placebo (mean¡S.E.) : 37.12¡
8.21 mg/dlr240 min; t=3.06, p<0.01].
The minimum ACTH detectable value (10 pg/ml)
was utilized instead of the results below the sensitivity
limit, as this occurred with most samples (193 out
of 270).
The decrease of ACTH concentrations was sig-
niﬁcant [time factor, F(8, 112)=2.27, p<0.05] and
similar for both groups [treatment factor, F(1, 14)=
1.63, p>0.05]. There was no signiﬁcant treat-
mentrtime interaction [interaction factor, F(8, 112)=
1.72, p>0.05], neither did the total secretion of
ACTH diﬀer between the two groups [quetiapine
(mean¡S.E.) : 44.34¡6.03 pg/mlr 240 min; placebo
(mean¡S.E.) : 43.57¡4.33 pg/mlr 240 min; t=1.00,
p>0.05].
Several GH results were below the method sensi-
tivity (125 out of 270), and thus, the minimum detec-
tion value used was 0.1 ng/ml.
As shown in Figure 3, GH concentrations were not
signiﬁcantly diﬀerent with quetiapine and placebo up
to 180 min. Then, there was an increase in the hor-
mone levels for both groups [time factor, F(8, 112)=
7.17, p<0.001], although this was more intense in
the quetiapine group after 210 min. There were sig-
niﬁcant treatmentrtime interactions [interaction fac-
tor, F(8, 112)=3.88, p<0.001]. There was no signiﬁcant
diﬀerence between quetiapine and placebo [treatment
factor, F(1, 14)=1.01, p>0.05]. After Greenhouse–
Geisser and Huynh–Feldt corrections, diﬀerences
remained signiﬁcant. The total GH secretion did not
diﬀer between the groups [quetiapine (mean¡S.E.) :
7.84¡9.28 ng/mlr240 min; placebo (mean¡S.E) :
6.54¡7.37 ng/mlr240 min; t=0.67, p>0.05].
None of the volunteers reported side-eﬀects with
the use of placebo. After the ingestion of quetiapine,
all of them had somnolence in the ﬁrst evaluation
(t=120 min), as had 14 of them in the second
evaluation (t=240 min) ; approximately half of the
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Figure 2.Mean (¡S.E.) cortisol plasma levels (mg/ml) after the administration of 150 mg quetiapine (–&–) and placebo (- -$- -)
to healthy volunteers (n=15). Two-way ANOVA factors : treatment F(1, 14)=10.83, p<0.01 ; time F(8, 112)=26.82, p<0.001 ;
interaction F(8, 112)=11.20, p<0.001. Tukey’s tests : * p<0.001, compared to baseline ; # p<0.001, compared to placebo. Inset :
mean (¡S.E.) area under curve (AUC) for 150 mg quetiapine and placebo. Paired t test=3.06, # p<0.01.
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volunteers (seven) had moderate somnolence in the
middle of the experiment and mild somnolence at
the end of observation period. Nine volunteers com-
plained of mild xerostomia in the ﬁrst evaluation,
but only two of them in the second evaluation. In the
ﬁrst evaluation, four volunteers had dizziness, one
tachycardia and another one headache, all of mild
intensity.
Discussion
The increased Prl secretion found in this study is
consistent with results from previous studies on
the neuroendocrine eﬀects of atypical antipsychotics
(Gudelsky et al., 1987 ; Kapur and Remington, 2001 ;
Kapur and Seeman, 2001 ; Turrone et al., 2002), in-
cluding a recent one using quetiapine (Kapur et al.,
2000). It is presumably secondary to the high transi-
tory occupation of D2 receptors at the anterior pitu-
itary (Kapur et al., 2000; Turrone et al., 2002).
However, our study design did not allow to an ad-
equate evaluation of this transient Prl increase, since
the last blood sample was only drawn up to 4 h after
the administration of quetiapine.
The secretion of Prl, although mainly controlled by
the dopaminergic system, is also under the inﬂuence
of other systems. Clinical studies have demonstrated
histaminergic inﬂuences on the Prl secretion (Knigge
et al., 1986a; Pontiroli et al., 1981). The hormonal
stimulation mediated by H1 receptors seemed related
to inhibition of the dopaminergic system, whereas
hormonal inhibition, via H2 receptors, did not appear
to involve dopamine (Knigge et al., 1986a). Interest-
ingly, the role of histaminergic receptors on Prl
secretion in rats depends on the route of histamine
administration : the intracerebroventricular injection
stimulates Prl, probably through H2 receptors and
promotes hormonal inhibition through H1 receptors ;
whereas systemic administration induces opposite
eﬀects (Knigge et al., 1986b). Serotonergic stimuli in-
crease Prl secretion in humans and in rats (Albinsson
et al., 1994 ; Gartside and Cowen, 1990; Jørgensen
et al., 1993, 1996; Lowy and Meltzer, 1988). This eﬀect,
in rats, seems to be a result of both the combined ac-
tivation of 5-HT1, 5-HT2 and 5-HT3 receptors and the
interaction between 5-HT1 and 5-HT2 receptors with
the H1 and H2 histaminergic receptors (Jørgensen
et al., 1996). Sigma receptors might also participate in
the control of Prl secretion via the modulation of the
dopaminergic system (Eaton et al., 1996 ; Gudelsky
and Nash, 1992), but results of studies in rats are
controversial : ligands with a high aﬃnity for these
9
8
7
6
5
4
3
2
1
0
0 30 60 90 120 150 180 210 240
Time (min)
G
H
 (
n
g
/m
l)
G
H
A
U
C
 (
n
g
/m
l ×
 2
40
 m
in
)
15
10
5
0
Placebo Quetiapine
Figure 3.Mean (¡S.E.) GH plasma levels (ng/ml) after the administration of 150 mg quetiapine (–&–) and placebo (- -$- -)
to healthy volunteers (n=15). Two-way ANOVA factors : time F(8, 112)=7.17, p<0.001 ; interaction F(8, 112)=3.88, p<0.001 ;
treatment F(1, 14)=1.01, p>0.05. Tukey’s tests : * p<0.001, compared to baseline ; # p<0.05, compared to placebo. Inset : mean
(¡S.E) area under curve (AUC) for 150 mg quetiapine and placebo. Paired t test=0.67, p>0.05.
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receptors induce both increase (Gudelsky and Nash,
1992) and reduction of Prl concentrations (Eaton et al.,
1996 ; Karbon et al., 1993). In addition, noradrenergic
antagonism, via a2 receptors, stimulates Prl secretion
in rats, probably through a direct eﬀect on the anterior
pituitary (Kiem et al., 1995; Krulich et al., 1989).
It is conceivable that the quetiapine increase of Prl
secretion was due to its dopaminergic eﬀects as
its antagonism of histaminergic and serotonergic re-
ceptors were not enough to counterbalance the dopa-
minergic stimulus. The plasma Prl levels were often
higher than 20 ng/ml, although probably transitory,
reaching a value considered as hyperprolactinaemia
for men (Halbreich et al., 2003). There are several
clinical eﬀects of sustained hyperprolactinaemia and
they have been well described, but it is still unknown
whether daily Prl ﬂuctuations, including values higher
than those within the normal range, such as observed
with some of the atypical antipsychotics, are com-
pletely safe. In fact, a recent study reported on delu-
sions of pregnancy associated with increased Prl
concentrations, probably due to the rising of the hor-
monal levels (Ali et al., 2003). Thus, it should be borne
in mind that the statement ‘atypical antipsychotics
do not induce Prl elevation’ may not be completely
true as these brief and transient hormonal elevations
need further studies, including long-term eﬀects and
potential clinical consequences.
The reduction of Cor concentrations after the ad-
ministration of quetiapine may be due to its antagon-
ism on H1, s, a1, 5-HT2 and D2 receptors. It has been
shown that these receptors’ antagonism inhibit the
release of Cor in humans (Asnis et al., 1992 ; Laakmann
et al., 1999 ; Lowy andMeltzer, 1988 ; Monteleone et al.,
1991 ; Sargent et al., 1998; Schilling et al., 1992 ; Schu¨le
et al., 2002) and of corticosterone in rats (Bagdy, 1996;
Eaton et al., 1996 ; Gudelsky and Nash, 1992 ; Owens
et al., 1991; Tsujimoto et al., 1993). Quetiapine’s
antagonism on the a2 adrenergic receptors was not
enough to prevent the Cor decrease. Diurnal decline
in Cor level at the time of the experiment may have
contributed to these results but, as the reduction
with quetiapine was steeper than that observed with
placebo, pharmacological action was probably the
main reason for the diﬀerence.
Studies have demonstrated that histaminergic acti-
vation in rats stimulates ACTH release (Knigge et al.,
1989), probably through a release of oxytocin and
corticotropin-releasing hormone (CRH) due to an in-
crease of RNAm in hypothalamic neurons. This eﬀect
is mediated by both H1 and H2 receptors (Kjær et al.,
1998). In humans, H1 antagonists blunted the ACTH
increase induced by hypoglycaemia or metyrapone
(Allolio et al., 1980). Besides, s receptors agonists
produced an increase in ACTH secretion in rats (Eaton
et al., 1996; Iyengar et al., 1991; Pechnick and Poland,
1994), and such an eﬀect did not seem to be caused by
a direct action on the pituitary, since it did not happen
in vitro, i.e. cultures of pituitary cells (Iyengar et al.,
1990). Interestingly, the activation of a1 adrenergic,
5-HT2 serotonergic and D2 dopaminergic receptors
is capable of increasing ACTH secretion in rats
(Borowsky and Kuhn, 1992 ; Calogero et al., 1993;
Gartside and Cowen, 1990; Labrie et al., 1984 ; Levy
and Van der Kar, 1992 ; Owens et al., 1991 ; Tuomisto
and Mannisto, 1985). In humans, the activation of D2
receptors in hypothalamic dopaminergic neurons also
produced an ACTH increase (Tuomisto and Mannisto,
1985), but a study with four volunteers did not detect
any change in this hormone secretion after the
administration of ketanserin (a 5-HT2 antagonist)
(Gordin et al., 1985).
Thus, a reduction in ACTH levels was expected as
a consequence of quetiapine’s antagonistic action in
H1, s, a1, 5-HT2 and D2 receptors. However, there
were no signiﬁcant diﬀerences between the groups,
probably due to the ‘ground eﬀect’, i.e. most of
the results where below the sensitivity of the assay.
Unfortunately our study did not use any challenge test
in order to stimulate ACTH release before the admin-
istration of quetiapine. Such limitation with the ACTH
results may explain the contrast between Cor decrease
and ACTH non-response. Since the secretion of both
hormones is closely related (Aron et al., 2001), either
the test was not capable of detecting a parallel ACTH
decrease or a direct action in the adrenal glands was
responsible for the Cor response.
The intracerebroventricular administration of hista-
minergic agonists in rats inhibits the pharmacologi-
cally induced GH release and its pulsatile secretion
(Netti et al., 1982 ; Roberts and Calcutt, 1983).
Therefore, quetiapine’s high antagonism on H1 re-
ceptors could stimulate GH secretion.
The antagonism of 5-HT2 serotonergic receptors
with ketanserin and ritanserin did not produce
changes in GH basal levels in two studies with
healthy volunteers (Gordin et al., 1985 ; Pontiroli et al.,
1981). Another study in healthy volunteers, using the
5-HT2 agonist MK-212, did not demonstrate signiﬁ-
cant changes in GH concentrations either (Lowy and
Meltzer, 1988). The intravenous administration of 5-
hydroxytryptophan (serotonin precursor) increases
GH secretion but this eﬀect may be mediated by
dopaminergic rather than serotonergic neurotransmis-
sion (van Praag et al., 1986). The lack of response
of GH levels to the blockade or the activation of
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5-HT2 receptors suggests that such an increase is
mediated by other serotonergic receptors (Anderson
and Cowen, 1986 ; Pontiroli et al., 1981). Agonists
of the a2 adrenergic receptors stimulate GH release
(Amsterdam et al., 1989; Gaynor et al., 1993 ; Lima
et al., 1993 ; Netti et al., 1993). A study with cattle
(McMahon et al., 2001) suggests that the inhibition of
somatostatin release, at the periventricular nucleus,
and the direct stimulation of the GH releasing
hormone (GHRH) release at the median eminence,
would be the mechanisms responsible for the increase
in GH. Dopaminergic (D2) agonists, as well as a2
adrenergic agonists, produce, in humans, increase of
GH concentrations (de Visser et al., 2001; Schilling
et al., 1992). The increase in GH levels in response to
quetiapine could have been prevented by all these
actions, but it did not occur. Besides pharmacological
factors and in spite of the eﬀort to keep volunteers
awake to avoid sleep’s interference on hormonal
secretion, short naps could not be completely pre-
vented and might have also contributed to GH in-
crease. Pulsatile GH secretion (Finkelstein et al., 1972)
could be another explanation to our results since
medium GH increase was due to elevations from 8 out
of 15 volunteers.
The somnolence induced by quetiapine has been
attributed to the high aﬃnity for H1 receptors as
well as the moderate aﬃnity for a1 receptors (Garver,
2000 ; Green, 1999). In this study, this eﬀect was
pronounced, possibly due to the administration of
150 mg quetiapine as an initial dose. This dose,
although the low limit of the therapeutic range, is
triple the recommended initial dose. It was chosen
to evaluate quetiapine’s eﬀects within the therapeutic
range instead of using subclinical doses. Dizziness
could be another symptom of sedation, as well as
somnolence (Garver, 2000; Green, 1999). Xerostomia
cannot be explained by an action on muscarinic re-
ceptors, since quetiapine has a low aﬃnity (IC50>
10 000 nM) for them. A reason for it may be the re-
duction of the cholinergic activity indirectly produced
by the histaminergic (H1) antagonism (Garver, 2000).
Furthers studies, measuring blood levels for
quetiapine in a dose–response fashion, are necessary
to conﬁrm and clarify the present ﬁndings.
Acknowledgements
This work has been supported by the following
research funding agencies: the National council for
Scientiﬁc and Technological Development (CNPq)
and the Association and Fund for the Promotion of
Psychopharmacology (AFIP).
Statement of Interest
Dr Calil has received speaker fees or grant studies
from Astra-Zeneca, Bristol–Myers–Squibb, Eli-Lilly,
Elsevier, Novartis, Organon, Pierre Fabre, Pﬁzer and
Wyeth andDr Castel has received speaker fees or grant
studies from Astra-Zeneca, Roche and sponsorships
from the Canadian Institute of Health Research and
the Association of Support for Psychopharmacology –
Department of Psychobiology – Federal University of
Sao Paulo.
References
Albinsson A, Palazidou E, Stephenson J, Andersson G
(1994). Involvement of the 5-HT2 receptor in the 5-HT
receptor-mediated stimulation of prolactin release.
European Journal of Pharmacology 251, 157–161.
Ali JA, Desai KD, Ali LJ (2003). Delusions of pregnancy
associated with increased prolactin concentrations
produced by antipsychotic treatment. International Journal
of Neuropsychopharmacology 6, 111–115.
Allolio B, Winkelmann W, Deuss U, Heesen D, Hipp FX,
Miles R (1980). Eﬀect of antihistaminic agent meclastine on
plasma ACTH. Acta Endocrinologica (Copenhagen) 94,
143–144.
Amsterdam JD, Maislin G, Skolnick B, Berwish N,
Winokur A (1989). Multiple hormone responses to
clonidine administration in depressed patients and healthy
volunteers. Biological Psychiatry 26, 265–278.
Anderson IM, Cowen PJ (1986). Clomipramine enhances
prolactin and growth hormone responses to L-tryptophan.
Psychopharmacology 89, 131–133.
Aron DC, Findling JW, Tyrrell JB (2001). Glucocorticoids
and adrenal androgens. In : Greenspan FS, Gardner DG
(Eds.), Basic and Clinical Endocrinology (pp. 334–376).
New York : McGraw-Hill.
Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study
Group (1997). Multiple ﬁxed doses of ‘Seroquel’
(quetiapine) in patients with acute exacerbation of
schizophrenia : a comparison with haloperidol and
placebo. Biological Psychiatry 42, 233–246.
Asnis GM, Sanderson WC, van Praag HM (1992).
Cortisol response to intramuscular desipramine in
patients with major depression and normal control
subjects : a replication study. Psychiatry Research 44,
237–250.
Bagdy G (1996). Role of the hypothalamic paraventricular
nucleus in 5-HT1A, 5-HT2A, 5-HT2C receptor-mediated
oxytocin, prolactin and ACTH/corticosterone responses.
Behavioural Brain Research 73, 277–280.
Borowsky B, Kuhn CM (1992). D1 and D2 dopamine
receptors stimulate hypothalamo-pitiutary-adrenal
activity in rats. Neuropharmacology 31, 671–678.
Caccia S (2000). Biotransformation of post-clozapine
antipsychotics. Clinical Pharmacokinetics 38, 393–414.
Neuroendocrine eﬀects of quetiapine in healthy volunteers 55
 by guest on June 1, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Calogero AE, Bagdy G, Moncada ML, D’agata R (1993).
Eﬀect of selective agonists on basal, corticotrophin-
releasing hormone- and vasopressin-induced ACTH
release in vitro from rat pituitary cells. Journal of
Endocrinology 136, 381–387.
De Visser SJ, van der Post J, Pieters SM, Cohen AF,
van Gerven JMA (2001). Biomarkers for the eﬀects of
antipsychotic drugs in healthy volunteers. British Journal
of Clinical Pharmacology 51, 119–132.
Eaton MJ, Lookingland KJ, Moore KE (1996). The s receptor
ligand rimcazole alters secretion of prolactin and a-
melanocyte stimulating hormone by dopaminergic and
non-dopaminergic mechanisms. European Journal of
Pharmacology 299, 171–177.
Finkelstein JW, Roﬀwarg HP, Boyar RM, Kream J,
Hellman L (1972). Age-related change in the twenty-
four-hour spontaneous secretion of growth hormone.
Journal of Clinical Endocrinology and Metabolism 35,
665–670.
First MB, Gibbon MSW, Spitzer RL, Williams JBW (1996).
User’s Guide for the Structured Clinical Interview for DSM-IV
Axis I Disorders – Research Version (SCID-I, version 2.0). New
York : Biometrics Research.
Gartside SE, Cowen PJ (1990). Mediation of ACTH and
prolactin responses to 5-HTP by 5-HT2 receptors. European
Journal of Pharmacology 179, 103–109.
Garver DL (2000). Review of quetiapine side eﬀects. Journal of
Clinical Psychiatry 61 (Suppl. 8), 31–33.
Gaynor PJ, Chapin LT, Lookingland KJ, Tucker HA (1993).
a2-Adrenergic receptor-mediated regulation of growth
hormone secretion in meal-fed Holstein steers (43669).
Proceedings of the Society for Experimental Biology and
Medicine 204, 318–322.
Gordin A, Mustajoki P, Pelkonen R (1985). Ketanserin
without eﬀects on basal anterior pituitary hormone
secretion in healthy subjects. Journal of Endocrinological
Investigation 8, 73–75.
Green B (1999). Focus on quetiapine. Current Medical Research
and Opinion 15, 145–151.
Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori
T, Meltzer HY (1987). Journal of Neural Transmission 68,
227–240.
Gudelsky GA, Nash JF (1992). Neuroendocrinological and
neurochemical eﬀects of sigma ligands. Neuropharmacology
31, 157–162.
Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003).
Elevated prolactin levels in patients with schizophrenia :
mechanisms and related adverse eﬀects. Psychoneuro-
endocrinology 28, 53–67.
Iyengar S, Mick S, Dilworth VM, Michel J, Rao TS, Farah
JM, Wood PL (1990). Sigma receptors modulate the
hypothalamic-pituitary-adrenal (HPA) axis centrally :
evidence for a functional interaction with NMDA
receptors, in vivo. Neuropharmacology 29, 299–303.
Iyengar S, Wood PL, Mick SJ, Dilworth VM, Gray NM,
Farah JM, Rao TS, Contreras PC (1991). (+)3-[3-
hydroxyphenyl-N-(1-propyl) piperidine] selectively
diﬀerentiates eﬀects of sigma ligands on neurochemical
pathways modulated by sigma receptors : evidence for
subtypes, in vivo. Neuropharmacology 30, 915–922.
Jørgensen H, Knigge U, Kjær A, Warberg J (1996).
Interactions of histaminergic and serotonergic neurons in
the hypothalamic regulation of prolactin and ACTH
secretion. Neuroendocrinology 64, 329–336.
Jørgensen H, Knigge U, Warberg J (1993). Eﬀect of selective
serotonin receptor agonists on prolactin secretion in male
rats. Neuroendocrinology 57, 401–407.
Kapur S, Remington G (2001). Atypical antipsychotics :
new directions and challenges in the treatment of
schizophrenia. Annual Review of Medicine 52, 503–517.
Kapur S, Seeman P (2001). Does fast dissociation from the
dopamine D2 receptor explain the action of atypical
antipsychotics? : a new hypothesis. American Journal of
Psychiatry 158, 360–369.
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G,
Seeman P (2000). A positron emission tomography study
of quetiapine in schizophrenia a preliminary ﬁnding of an
antipsychotic eﬀect with only transiently high dopamine
D2 receptor occupancy. Archives of General Psychiatry 57,
553–559.
Karbon EW, Abreu ME, Erickson RH, Kaiser C, Natalie
Jr. KJ, Clissold DB, Borosky S, Bailey M, Martin LA,
Pontecorvo MJ (1993). NPC 16377, a potent and selective
s-ligand. I. receptor binding, neurochemical and
neuroendocrine proﬁle. Journal of Pharmacology and
Experimental Therapeutics 265, 866–874.
Kiem DT, Barna I, Koenig JI, Makara GB (1995).
Adrenocorticotropin, prolactin and beta-endorphin
stimulatory actions of alpha-2-adrenoceptor antagonists.
Neuroendocrinology 61, 152–158.
King DJ, Link CGG, Kowalcyk B (1998). A comparison of
bid and tid dose regimens of quetiapine (Seroquel) in the
treatment of schizophrenia. Psychopharmacology (Berlin)
137, 139–146.
Kjær A, Larsen PJ, Knigge U, Jørgensen H,Warberg J (1998).
Neuronal histamine and expression of corticotropin-
releasing hormone, vasopressin and oxytocin in the
hypothalamus : relative importance of H1 and H2 receptors.
European Journal of Endocrinology 139, 238–243.
Knigge U, Matzen S, Bach FW, Bang P, Warberg J (1989).
Involvement of histaminergic neurons in the stress-
induced release of pro-opiomelanocortin-derived peptides
in rats. Acta Endocrinologica (Copenhagen) 120, 533–539.
Knigge U, Matzen S, Warberg J (1986b). Histaminergic
stimulation of prolactin secretion mediated via H1- or
H2-receptors : dependence on routes of administration.
Neuroendocrinology 44, 41–48.
Knigge U, Thuesen B, Christiansen PM (1986a).
Histaminergic regulation of prolactin secretion : dose
response relationship and possible involvement of the
dopaminergic system. Journal of Clinical Endocrinology and
Metabolism 62, 491–496.
Krulich L, Jurcovicova J, Le T (1989). Prolactin (PRL)
release-inhibiting properties of the a2 adrenergic receptor
antagonist idazoxan: comparison with yohimbine. Life
Sciences 44, 809–818.
56 A. de Borja Gonc¸alves Guerra et al.
 by guest on June 1, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Laakmann G, Schu¨le C, Baghai T, Waldvogel E (1999).
Eﬀects of mirtazapine on growth hormone, prolactin, and
cortisol secretion in healthy male volunteers. Psychoneuro-
endocrinology 24, 769–784.
Labrie F, Giguere V, Proulx L, Lefevre G (1984). Interactions
between CRF, epinephrine, vasopressin and
glucocorticoids in the control of ACTH secretion.
Journal of Steroid Biochemistry 20, 153–160.
Levy AD, Van der Kar LD (1992). Endocrine and receptor
pharmacology of serotonergic anxyolitics, antipsychotics
and antidepressants. Life Sciences 51, 83–94.
Lima L, Arce V, Tresguerres JAF, Devesa J (1993). Clonidine
potentiates the growth hormone (GH) response to GH-
releasing hormone in norepinephrine synthesis-inhibited
rats : evidence for an alpha-2-adrenergic control of
hypothalamic release of somatostatin. Neuroendocrinology
57, 1155–1160.
Lingjaerde O, Ahlfors UG, Bech P, Denker SJ, Elgen K
(1987). The UKU side eﬀect rating scale. Acta Psychiatrica
Scandinavica 76 (Suppl. 334), 81–94.
Lowy MT, Meltzer HY (1988). Stimulation of serum
cortisol and prolactin secretion in humans by MK-212, a
centrally active serotonin agonist. Biological Psychiatry 23,
818–828.
Markowitz JS, Brown CS, Moore TR (1999). Atypical
antipsychotics part I : Pharmacology, pharmacokinetics,
and eﬃcacy. Annals of Pharmacotherapy 33, 73–85.
McMahon CD, Chapin LT, Radcliﬀ RP, Lookingland
KJ, Tucker HA (2001). Somatostatin inhibits alpha-2-
adrenergic-induced secretion of growth hormone-
releasing hormone. Neuroendocrinology 73, 417–425.
Meltzer HY, Deutch AY (1999). Neurochemistry of
schizophrenia. In : Siegel GJ, Agranoﬀ BW, Albers RW,
Fisher SK, Uhler MD (Eds.), Basic Neurochemistry :
Molecular, Cellular and Medical Aspects (pp. 1053–1072).
Philadelphia : Lippincott-Raven.
Monteleone P (1991). Eﬀects of trazodone on plasma cortisol
in normal subjects. A study with drug plasma levels.
Neuropsychopharmacology 5, 61–64.
Netti C, Guidobono F, Olgiati VR, Sibilia V, Pagani F,
Pecile A (1982). Inﬂuence of brain histaminergic system
on episodic growth hormone secretion in the rat.
Neuroendocrinology 35, 43–47.
Netti C, Sibilia V, Guidobono F, Pecile A (1993). Inﬂuence of
brain histamine on growth hormone secretion induced by
alpha-2-receptor activation. Neuroendocrinology 57,
1066–1070.
Owens MJ, Knight DL, Ritchie JC, Nemeroﬀ CB (1991).
The 5-hydroxytryptamine2 agonist, (¡)-1-(2,5-
dimethoxy-4-bromophenyl)-2-aminopropane stimulates
the hypothalamic-pituitary-adrenal (HPA) axis. II.
Biochemical and physiological evidence for the
development of tolerance after chronic administration.
Journal of Pharmacology and Experimental Therapeutics 256,
795–800.
Pechnick RN, Poland EP (1994). Neuroendocrine responses
produced by enantiomeric pairs of drugs that interact
with phencyclidine and s receptors. European Journal of
Pharmacology 263, 115–120.
Pontiroli AE, De Castro e Silva E, Mazzoleni F, AlberettoM,
Baio G, Pellicciotta G, De Pasqua A, Stella L, Girardi AM,
Pozza G (1981). The eﬀect of histamine and H1 and H2
receptors on prolactin and luteinizing hormone release
in humans : sex diﬀerences and the role of stress.
Journal of Clinical Endocrinology and Metabolism 52,
924–928.
Roberts F, Calcutt CR (1983). Histamine and the
hypothalamus. Neuroscience 9, 721–739.
Sargent PA, Quested DJ, Cowen PJ (1998). Clomipramine
enhances the cortisol response to 5-HTP: implications for
the therapeutic role of 5-HT2 receptors. Psychopharmacology
(Berlin) 140, 120–122.
Schilling JC, Adamus WS, Palluk R (1992). Neuroendocrine
and side eﬀect proﬁle of pramipexole, a new dopamine
receptor agonist, in humans. Clinical Pharmacology and
Therapeutics 51, 541–548.
Schu¨le C, Baghai T, Goy J, Bidlingmaier M, Strasburger C,
Laakmann G (2002). The inﬂuence of mirtazapine on
anterior pituitary hormone secretion in healthy male
subjects. Psychopharmacology 163, 95–101.
Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG
(1997). Quetiapine in patients with schizophrenia. A high-
and low-dose double-blind comparison with placebo.
Archives of General Psychiatry 54, 549–557.
Tuomisto J, Mannisto P (1985). Neurotransmitter regulation
of anterior pituitary hormones. Pharmacological Reviews 37,
249–332.
Tsujimoto S, Okumura Y, Kamei C, Tasaka K (1993). Eﬀects
of intracerebroventricular injection of histamine and
related compounds on corticosterone release in rats.
British Journal of Pharmacology 109, 807–813.
Turrone P, Kapur S, Seeman MV, Flint AJ (2002).
Elevation of prolactin levels by atypical antipsychotics.
American Journal of Psychiatry 159, 133–135.
Van Praag HM, Lemus C, Kahn R (1986). The pitfalls
of serotonin precursors as challengers in hormonal
probes of central serotonin activity. Psychopharmacology
Bulletin 22, 565–570.
Wetzel H, Szegedi A, Hain Ch, Wiesner J, Schlegel S,
Benkert O (1995). Seroquel (ICI 204 636), a putative
‘atypical’ antipsychotic, in schizophrenia with positive
simptomatology : results of an open clinical trial and
changes of neuroendocrinological and EEG parameters.
Psychopharmacology (Berlin) 119, 231–238.
Neuroendocrine eﬀects of quetiapine in healthy volunteers 57
 by guest on June 1, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
